A Phase 3 interventional study of Enzalutamide and Placebo in Progressive Metastatic Prostate Cancer, sponsored by Astellas Pharma Inc. Completed at 47 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.
Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Purpose of the study was to assess the effect of enzalutamide on time to Prostate Specific Antigen (PSA) progression as compared to placebo in chemotherapy naïve participants with progressive metastatic prostate cancer who have failed androgen deprivation therapy.
The study was a multinational Phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of oral enzalutamide (formerly MDV3100) in asymptomatic or mildly symptomatic participants with progressive metastatic prostate cancer who have disease progression despite androgen deprivation therapy. In order to join the study, participants could not have been previously treated with cytotoxic chemotherapy. Approximately 30 Chinese participants were allocated to the pharmacokinetic (PK) cohort. Participants in the PK cohort were required to be hospitalized from Day 1 before the randomization date to at least the completion of all the assessments planned on Day 3. All participants in the PK cohort underwent blood sampling for the PK analysis. Data reported in the results section was based on data cutoff dates of 20 Sept 2015 for efficacy and safety data and 20 Jan 2016 for PK outcome measures. The study completed double-blind period and is now in the open-label period.
57 studies on the registry are indexed under Bulbo-Spinal Atrophy, X-Linked; 12 are open to participants now.
This study's enrollment of 395 is above the median of 42 across 42 interventional studies indexed under Bulbo-Spinal Atrophy, X-Linked.
Browse Bulbo-Spinal Atrophy, X-Linked studies →Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 160 mg of enzalutamide orally once a day during double blind period until Prostate-Specific Antigen (PSA) progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer. Eligible participants who received enzalutamide during double blind and who provided consent to take part in open-label period continued to receive 160 mg of enzalutamide in open-label period orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
Drug: Enzalutamide
Participants received enzalutamide matching placebo orally once a day during double-blind period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
Drug: Placebo
Eligible participants who received enzalutamide matching placebo during double-blind period and who provided consent to take part in open-label period, received 160 mg of enzalutamide orally once a day during open-label period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
Drug: Enzalutamide
Oral
Also known as: Xtandi, MDV3100
Oral
Time to Prostate-specific Antigen (PSA) Progression
The time to Prostate Specific Antigen (PSA) progression was defined as the time from randomization to the PSA progression. The PSA progression was defined according to the consensus guidelines of Prostate Cancer Clinical Trials Working Group 2 (PCWG2).For participants with PSA decline at Week 13, the PSA progression date was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir, which would be confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at Week 13, the PSA progression date was defined as the date when a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later. Time to PSA progression was estimated using the Kaplan-Meier method. Participants without confirmed PSA progression were censored.
Time frame: From the date of randomization to PSA progression median follow-up time is 6.47 months for enzalutamide and 2.99 months for placebo
Duration of Overall Survival
Duration of overall survival was defined as the time from the randomization to deaths from any cause. For participants who were alive at the time of the data analysis, overall survival time was censored to the last know date the participants were known to be alive.
Time frame: From the date of randomization to deaths from any cause median follow-up time is 42.32 months for enzalutamide and 26.81 months for placebo
Duration of Radiographic Progression-free Survival (rPFS) Based on Independent Central Review Facility Assessment
Duration of Radiographic Progression-free Survival (rPFS) was defined as the time from randomization to the rPFS event (deaths from any cause and radiographic disease progression). Radiographic disease progression is defined by RECIST 1.1 for soft tissue disease, or PCWG2 for bone lesions. If a participant met the criteria for more than 1 censoring rule, they were censored with the earliest censoring date. The radiographic progression date was the first date when progression definition was met, not confirmed.
Time frame: From the date of randomization to the rPFS event (deaths from any cause and radiographic disease progression) median follow-up time is 5.55 months for enzalutamide and 3.71 months for placebo
Time to First Skeletal-Related Event
Time to first skeletal-related event (SRE) was defined as the time from randomization to the first skeletal-related event, defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of anti-neoplastic therapy to treat bone pain. Participants who have not had a SRE at the time of the analysis were censored at their last assessment indicating no evidence of SRE.
Time frame: From the date of randomization to the first skeletal-related event median follow-up time is 7.39 months for enzalutamide and 5.29 months for placebo
Time to Initiation of Cytotoxic Chemotherapy
Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to initiation of cytotoxic chemotherapy. It included only therapies for prostate cancer. When multiple cytotoxic chemotherapies were initiated, the first chemotherapy was used to determine the time to event. Participants who did not start cytotoxic chemotherapy at the time of analysis data cutoff were censored at the date of their last assessment indicating no evidence of cytotoxic chemotherapy usage.
Time frame: From the date of randomization to initiation of cytotoxic chemotherapy median follow-up time is 7.39 months for enzalutamide and 5.19 months for placebo
Number of Participants With Confirmed Best PSA Response (≥50% Decrease From Baseline)
Best PSA response was defined as as ≥50% reductions in PSA level from baseline to the lowest post-baseline PSA result as determined by the central laboratory, with a consecutive assessment conducted at least 3 weeks later to confirm the PSA response. Only participants who had both baseline and post-baseline assessments were included in the analysis.
Time frame: From baseline to the lowest post-baseline PSA result median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo
Best Overall Soft Tissue Response
Participants with measurable soft tissue disease at screening visit (i.e., at least one target lesion per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) who have an objective response (complete response (CR) or partial response (PR)) during the study were included in the best overall soft tissue response assessment. The best overall soft tissue response was based on the investigator assessment using RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.
Time frame: From the date of randomization median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo
Time to Maximum Concentration (Tmax) of Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
Maximum Observed Plasma Concentration During the First 24 Hours After Dosing (Cmax) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
AUC From the Time of Dosing to 24 h After Dosing (AUC24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
Concentration 24 h After Dosing (C24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2
N is the number of participants with available data at this time point.
Time frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
Observed Plasma Concentration in Predose Samples Obtained During Multiple-dose Administration of Minimum Concentration (Plasma Concentration at Pre Dose) (Cmin) Enzalutamide, M1,M2 and Enzalutamide Plus M2
N is the number of participants with available data at this time point.
Time frame: From the date of randomization up to Days 2, 3, 8, 22, 29, 43, 57, 85, 86, 113, 141 and 169
Apparent Total Systemic Clearance After Multiple Dosing (CL/F) Enzalutamide, M1,M2 and Enzalutamide Plus M2 (For Unchanged Enzalutamide Only)
Time frame: From the date of randomization up to Multiple Dosing Day 85
Peak-Trough Ratio (PTR) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame: From the date of randomization up to Multiple Dosing Day 85
AUC From the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame: From the date of randomization up to Multiple Dosing Day 85
Number of Participants With Adverse Events (AE)
An AE was defined as any untoward medical occurrence, temporally associated with use of medicinal product, whether considered related to medicinal product. AE could therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with use of a medicinal product. An AE was considered serious if, results in death; is life-threatening; results in persistent disability; results in congenital anomaly; requires inpatient hospitalization; or leads to prolongation of hospitalization; other medically important events. TEAE was defined as AE occurring from time of study drug administration on Day 1 until follow-up visit (28 days after last dose, or one day before date of initiation of cytotoxic chemotherapy or an investigational agent, whichever comes first). AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal.
Time frame: From first dose on Day 1 until 28 days after the last dose of study drug, or one day before the date of initiation of cytotoxic chemotherapy or an investigational agent for treatment of prostate cancer, whichever comes first, up to 123 months and 24 days
The study population consisted of men with asymptomatic or mildly symptomatic progressive metastatic prostate cancer, who had failed androgen deprivation therapy, and have not been treated with cytotoxic chemotherapy. Participants from 46 study sites in 4 countries (China, Korea, Taiwan and Hong Kong) were randomized for the study.
| Milestone | Enzalutamide | Placebo | Placebo Patients Crossover to Enzalutamide 160 mg |
|---|---|---|---|
| Started | 202 | 193 | 0 |
| Treated/received study drug | 202 | 193 | 0 |
| Completed | 84 | 1 | 0 |
| Not completed | 118 | 192 | 0 |
| Withdrew: Death | 6 | 4 | 0 |
| Withdrew: Miscellaneous | 30 | 66 | 0 |
| Withdrew: Withdrawal by subject | 27 | 54 | 0 |
| Withdrew: Protocol deviation | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Progressive disease | 38 | 51 | 0 |
| Withdrew: Adverse event | 16 | 15 | 0 |
| Milestone | Enzalutamide | Placebo | Placebo Patients Crossover to Enzalutamide 160 mg |
|---|---|---|---|
| Started | 85 | 0 | 51 |
| Completed | 0 | 0 | 0 |
| Not completed | 85 | 0 | 51 |
| Withdrew: Miscellaneous | 28 | 0 | 16 |
| Withdrew: Withdrawal by subject | 19 | 0 | 10 |
| Withdrew: Protocol deviation | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 2 |
| Withdrew: Progressive disease | 20 | 0 | 12 |
| Withdrew: Death | 6 | 0 | 5 |
| Withdrew: Adverse event | 6 | 0 | 6 |
The time to Prostate Specific Antigen (PSA) progression was defined as the time from randomization to the PSA progression. The PSA progression was defined according to the consensus guidelines of Prostate Cancer Clinical Trials Working Group 2 (PCWG2).For participants with PSA decline at Week 13, the PSA progression date was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir, which would be confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at Week 13, the PSA progression date was defined as the date when a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later. Time to PSA progression was estimated using the Kaplan-Meier method. Participants without confirmed PSA progression were censored.
| Months | Enzalutamide | Placebo |
|---|---|---|
| Time to Prostate-specific Antigen (PSA) Progression | 8.31 (5.72 to 10.25) | 2.86 (2.83 to 4.63) |
Duration of overall survival was defined as the time from the randomization to deaths from any cause. For participants who were alive at the time of the data analysis, overall survival time was censored to the last know date the participants were known to be alive.
| Months | Enzalutamide | Placebo |
|---|---|---|
| Duration of Overall Survival | 39.06 (29.24 to 57.63) | 27.10 (21.88 to 37.82) |
Duration of Radiographic Progression-free Survival (rPFS) was defined as the time from randomization to the rPFS event (deaths from any cause and radiographic disease progression). Radiographic disease progression is defined by RECIST 1.1 for soft tissue disease, or PCWG2 for bone lesions. If a participant met the criteria for more than 1 censoring rule, they were censored with the earliest censoring date. The radiographic progression date was the first date when progression definition was met, not confirmed.
| Months | Enzalutamide | Placebo |
|---|---|---|
| Duration of Radiographic Progression-free Survival (rPFS) Based on Independent Central Review Facility Assessment | NA (10.97 to NA) | 5.29 (3.61 to 11.33) |
Time to first skeletal-related event (SRE) was defined as the time from randomization to the first skeletal-related event, defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of anti-neoplastic therapy to treat bone pain. Participants who have not had a SRE at the time of the analysis were censored at their last assessment indicating no evidence of SRE.
| Months | Enzalutamide | Placebo |
|---|---|---|
| Time to First Skeletal-Related Event | NA (NA to NA) | NA (NA to NA) |
Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to initiation of cytotoxic chemotherapy. It included only therapies for prostate cancer. When multiple cytotoxic chemotherapies were initiated, the first chemotherapy was used to determine the time to event. Participants who did not start cytotoxic chemotherapy at the time of analysis data cutoff were censored at the date of their last assessment indicating no evidence of cytotoxic chemotherapy usage.
| Months | Enzalutamide | Placebo |
|---|---|---|
| Time to Initiation of Cytotoxic Chemotherapy | NA (NA to NA) | 13.93 (NA to NA) |
Best PSA response was defined as as ≥50% reductions in PSA level from baseline to the lowest post-baseline PSA result as determined by the central laboratory, with a consecutive assessment conducted at least 3 weeks later to confirm the PSA response. Only participants who had both baseline and post-baseline assessments were included in the analysis.
| Participants | Enzalutamide | Placebo |
|---|---|---|
| Number of Participants With Confirmed Best PSA Response (≥50% Decrease From Baseline) | 120 | 15 |
Participants with measurable soft tissue disease at screening visit (i.e., at least one target lesion per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) who have an objective response (complete response (CR) or partial response (PR)) during the study were included in the best overall soft tissue response assessment. The best overall soft tissue response was based on the investigator assessment using RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.
| Participants | Enzalutamide | Placebo |
|---|---|---|
| Best Overall Soft Tissue Response | 18 | 1 |
| hour | Enzalutamide | M1- Carboxylic Acid Metabolite | M2- N-Desmethyl Enzalutamide | Enzalutamide Plus M2 |
|---|---|---|---|---|
| Day 1 | 0.975 (0.500 to 6.05) | 24.0 (0.550 to 24.9) | 24.0 (0.550 to 24.9) | 0.975 (0.500 to 24.0) |
| Day 85 | 1.00 (0 to 2.00) | 1.02 (0.217 to 24.1) | 0 (0 to 23.8) | 0.250 (0 to 23.8) |
| micrograms/milliliter (μg/mL) | Enzalutamide | M1- Carboxylic Acid Metabolite | M2- N-Desmethyl Enzalutamide | Enzalutamide Plus M2 |
|---|---|---|---|---|
| Day 1 | 3.92 ± 1.37 | 0.112 ± 0.0794 | 0.175 ± 0.0921 | 3.94 ± 1.34 |
| Day 85 | 20.0 ± 3.22 | 14.0 ± 23.5 | 15.2 ± 3.44 | 34.2 ± 4.98 |
| μg*h/mL | Enzalutamide | M1- Carboxylic Acid Metabolite | M2- N-Desmethyl Enzalutamide | Enzalutamide Plus M2 |
|---|---|---|---|---|
| AUC From the Time of Dosing to 24 h After Dosing (AUC24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2 | 43.1 ± 9.64 | 1.81 ± 0.972 | 2.17 ± 1.30 | 45.3 ± 10.1 |
N is the number of participants with available data at this time point.
| μg/mL | Enzalutamide | M1- Carboxylic Acid Metabolite | M2- N-Desmethyl Enzalutamide | Enzalutamide Plus M2 |
|---|---|---|---|---|
| Day 1 | 1.65 ± 0.343 | 0.111 ± 0.0801 | 0.164 ± 0.0942 | 1.82 ± 0.363 |
| Day 85 | 17.6 ± 3.09 | 6.09 ± 3.07 | 13.7 ± 2.91 | 31.2 ± 4.00 |
N is the number of participants with available data at this time point.
| μg/mL | Enzalutamide | M1- Carboxylic Acid Metabolite | M2- N-Desmethyl Enzalutamide | Enzalutamide Plus M2 |
|---|---|---|---|---|
| Day 2 predose | 1.65 ± 0.343 | 0.111 ± 0.0801 | 0.164 ± 0.0942 | 1.82 ± 0.363 |
| Day 3 predose | 3.29 ± 1.16 | 0.302 ± 0.256 | 0.367 ± 0.188 | 3.66 ± 1.24 |
| Day 8 predose | 9.39 ± 2.07 | 1.21 ± 0.923 | 1.94 ± 0.983 | 11.3 ± 2.62 |
| Day 22 predose | 17.6 ± 2.37 | 6.09 ± 8.26 | 8.34 ± 2.74 | 25.9 ± 3.25 |
| Day 29 predose | 19.6 ± 4.00 | 8.16 ± 12.5 | 10.9 ± 3.72 | 30.5 ± 5.47 |
| Day 43 predose | 17.0 ± 4.13 | 12.5 ± 22.1 | 14.0 ± 3.99 | 31.0 ± 5.82 |
| Day 57 predose | 17.8 ± 3.09 | 18.4 ± 28.2 | 14.7 ± 3.88 | 32.5 ± 4.57 |
| Day 85 predose | 17.9 ± 3.19 | 6.33 ± 2.95 | 14.9 ± 3.67 | 32.8 ± 5.10 |
| Day 86 predose | 17.6 ± 3.09 | 6.09 ± 3.07 | 13.7 ± 2.91 | 31.2 ± 4.00 |
| Day 113 predose | 17.5 ± 4.14 | 17.5 ± 33.1 | 15.0 ± 3.21 | 32.5 ± 3.72 |
| Day 141 predose | 17.3 ± 3.73 | 5.52 ± 2.10 | 14.3 ± 3.90 | 31.6 ± 4.70 |
| Day 169 predose | 17.2 ± 5.55 | 5.09 ± 2.27 | 14.0 ± 4.80 | 31.2 ± 5.02 |
| L/h | Enzalutamide | M1- Carboxylic Acid Metabolite | M2- N-Desmethyl Enzalutamide | Enzalutamide Plus M2 |
|---|---|---|---|---|
| Apparent Total Systemic Clearance After Multiple Dosing (CL/F) Enzalutamide, M1,M2 and Enzalutamide Plus M2 (For Unchanged Enzalutamide Only) | 0.387 ± 0.0774 | NA ± NA | NA ± NA | NA ± NA |
| Ratio | Enzalutamide | M1- Carboxylic Acid Metabolite | M2- N-Desmethyl Enzalutamide | Enzalutamide Plus M2 |
|---|---|---|---|---|
| Peak-Trough Ratio (PTR) Enzalutamide, M1,M2 and Enzalutamide Plus M2 | 1.15 ± 0.110 | 1.19 ± 0.364 | 1.09 ± 0.0897 | 1.08 ± 0.0581 |
| μg*h/mL | Enzalutamide | M1- Carboxylic Acid Metabolite | M2- N-Desmethyl Enzalutamide | Enzalutamide Plus M2 |
|---|---|---|---|---|
| AUC From the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) Enzalutamide, M1,M2 and Enzalutamide Plus M2 | 427 ± 79.8 | 149 ± 74.1 | 308 ± 68.2 | 735 ± 109 |
An AE was defined as any untoward medical occurrence, temporally associated with use of medicinal product, whether considered related to medicinal product. AE could therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with use of a medicinal product. An AE was considered serious if, results in death; is life-threatening; results in persistent disability; results in congenital anomaly; requires inpatient hospitalization; or leads to prolongation of hospitalization; other medically important events. TEAE was defined as AE occurring from time of study drug administration on Day 1 until follow-up visit (28 days after last dose, or one day before date of initiation of cytotoxic chemotherapy or an investigational agent, whichever comes first). AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal.
| Participants | Enzalutamide | Placebo | Placebo Followed by Enzalutamide |
|---|---|---|---|
| Treatment Emergent Adverse Events (TEAEs) | 190 | 166 | 47 |
| Grade 3 or Higher TEAE | 98 | 66 | 28 |
| TEAE Leading to Death | 24 | 7 | 7 |
| Serious TEAE | 87 | 57 | 24 |
| TEAE That Was Primary Reason for Treatment Discontinuation | 32 | 33 | 7 |
| TEAE Leading to Study Drug Discontinuation | 49 | 42 | 12 |
| TEAE Leading to Dose Reduction of Study Drug | 4 | 3 | 2 |
| TEAE Leading to Dose Interruption of Study Drug | 28 | 16 | 7 |
| TEAE Related to Study Drug | 102 | 59 | 13 |
| Grade 3 or Higher TEAE Related to Study Drug | 26 | 13 | 5 |
| Serious TEAE Related to Study Drug | 14 | 7 | 3 |
Collected over All cause mortality: From the date of randomization up to 123 months and 24 days AE: From first dose on Day 1 until 28 days after the last dose of study drug, or one day before the date of initiation of cytotoxic chemotherapy or an investigational agent for treatment of prostate cancer, whichever comes first, up to 123 months and 24 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutamide | 85/202 (42.1%) | 87/202 (43.1%) | 169/202 (83.7%) |
| Placebo | 57/193 (29.5%) | 57/193 (29.5%) | 125/193 (64.8%) |
| Placebo Patients Crossover to Enzalutamide 160 mg | 21/51 (41.2%) | 24/51 (47.1%) | 31/51 (60.8%) |
| Event | Enzalutamide | Placebo | Placebo Patients Crossover to Enzalutamide 160 mg |
|---|---|---|---|
| PneumoniaInfections and infestations | 16/202 | 0/193 | 3/51 |
| HaematuriaRenal and urinary disorders | 8/202 | 6/193 | 0/51 |
| CataractEye disorders | 2/202 | 0/193 | 2/51 |
| NauseaGastrointestinal disorders | 0/202 | 0/193 | 2/51 |
| VomitingGastrointestinal disorders | 0/202 | 0/193 | 2/51 |
| Septic shockInfections and infestations | 2/202 | 1/193 | 2/51 |
| Spinal compression fractureInjury, poisoning and procedural complications | 1/202 | 0/193 | 2/51 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/202 | 0/193 | 2/51 |
| HydronephrosisRenal and urinary disorders | 3/202 | 1/193 | 2/51 |
| Urinary retentionRenal and urinary disorders | 7/202 | 2/193 | 1/51 |
| Event | Enzalutamide | Placebo | Placebo Patients Crossover to Enzalutamide 160 mg |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 30/202 | 16/193 | 10/51 |
| Decreased appetiteMetabolism and nutrition disorders | 37/202 | 19/193 | 6/51 |
| Back painMusculoskeletal and connective tissue disorders | 37/202 | 19/193 | 5/51 |
| FatigueGeneral disorders | 29/202 | 15/193 | 3/51 |
| ConstipationGastrointestinal disorders | 27/202 | 15/193 | 3/51 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 26/202 | 12/193 | 1/51 |
| Bone painMusculoskeletal and connective tissue disorders | 19/202 | 24/193 | 1/51 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 24/202 | 17/193 | 0/51 |
| Upper respiratory tract infectionInfections and infestations | 13/202 | 5/193 | 6/51 |
| NauseaGastrointestinal disorders | 23/202 | 11/193 | 2/51 |
Intent-to-treat (ITT) population consisted of all randomized participants in the study.
| Age, Continuous(Years) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| Mean | 71.6 ± 8.1 | 71 ± 8.7 | 71.3 ± 8.4 |
| Sex: Female, Male(Participants) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 202 | 193 | 395 |
| Race (NIH/OMB)(Participants) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 202 | 193 | 395 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Ran from Apr 2014 to primary completion in Sep 2015, 16 months.
Results were first posted in Apr 2017, 1 year 6 months after primary completion. A results delay was requested in Sep 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide
Bulbo-Spinal Atrophy, X-Linked →